In 2021, the FDA approved two new drugs for endocrinology-related indications, including severe hypoglycemia in diabetes, and chronic kidney disease (CKD) associated with type 2 diabetes. This article and slide deck explores each in more detail, including but not limited to their:
- target rationale
- discovery
- disease context
- original patents
- key clinical data
- pharmacokinetics
- industry history
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.